AOD-9604

Overview

The peptide was developed by Metabolic Pharmaceuticals, an Australian biotechnology company, with the specific goal of isolating the fat-metabolizing properties of growth hormone from its growth-promoting and diabetogenic effects. Full-length growth hormone (191 amino acids) provides powerful metabolic effects but also stimulates IGF-1 production, affects blood glucose regulation, and promotes cellular proliferation—all effects that complicate its therapeutic use for weight management.

Researchers discovered that the C-terminal fragment of hGH appeared responsible for many of growth hormone's lipolytic (fat-burning) effects while lacking the receptor binding capabilities that trigger IGF-1 release. By synthesizing just this fragment and adding a stabilizing tyrosine residue, they created AOD-9604—a peptide that could theoretically burn fat without the concerning side effects of full growth hormone therapy.

ℹ️ Historical Context: AOD-9604 progressed through Phase 2b/3 clinical trials for obesity treatment before development was discontinued in 2007. Despite the setback, the peptide later found new research applications in cartilage regeneration and joint health.

Unlike many research peptides that never progressed beyond animal studies, AOD-9604 has a substantial body of human clinical trial data. This provides valuable information about its safety profile and biological effects in humans, even though it never achieved regulatory approval as a weight loss therapeutic. The peptide has since gained renewed interest for its potential applications in joint health and cartilage regeneration, representing an unexpected pivot from its original metabolic focus.

AOD-9604's mechanism of action differs fundamentally from full-length growth hormone, which is precisely what makes it interesting for targeted fat metabolism research. Understanding this distinction requires examining how growth hormone normally works and why the C-terminal fragment behaves differently.

Research benefits

Stimulates lipolysis (fat breakdown) in adipose tissue

Does not affect blood glucose or insulin levels in studies

No increase in IGF-1 levels observed

Potential cartilage and joint regeneration properties

Well-tolerated in human clinical trials

Does not promote cell proliferation like full HGH

May reduce abdominal fat accumulation

Oral bioavailability demonstrated in some formulations

Research applications

Obesity and weight management

Active research area with published studies

Fat metabolism and lipolysis

Active research area with published studies

Cartilage regeneration and osteoarthritis

Active research area with published studies

Metabolic syndrome

Active research area with published studies

Body composition optimization

Active research area with published studies

Joint health and repair

Active research area with published studies

Growth hormone fragment biology

Active research area with published studies

Research findings

AOD-9604 benefits from a more extensive clinical research history than most peptides in the biohacking community. Its journey through formal pharmaceutical development generated substantial human data, while more recent studies have explored novel applications.

Obesity Clinical Trials

Metabolic Pharmaceuticals conducted multiple human trials of AOD-9604 for obesity treatment:

Phase 1 Studies: Initial safety studies in healthy volunteers established that AOD-9604 was well-tolerated across a range of doses. Importantly, these studies confirmed the peptide's key differentiating feature: it did not affect IGF-1 levels, blood glucose, or insulin sensitivity—distinguishing it from full growth hormone.

Phase 2 Trials: Proof-of-concept studies showed encouraging results. Obese participants receiving AOD-9604 demonstrated statistically significant reductions in body fat compared to placebo groups. Particularly notable was the reduction in visceral (abdominal) fat, which is metabolically the most concerning fat depot.

🔑 Clinical Trial Highlights

• Phase 2b/3 trial enrolled 536 obese participants over 24 weeks
• No significant effect on IGF-1, glucose, or insulin observed
• Reduction in abdominal fat was noted, though overall weight loss didn't reach significance
• Generally well-tolerated with mild, transient side effects

Phase 2b/3 Trial: The pivotal trial enrolled 536 obese participants in a 24-week, randomized, double-blind, placebo-controlled study. While the trial showed trends toward fat reduction—particularly abdominal fat—the primary endpoint of statistically significant weight loss compared to placebo was not achieved. The company cited issues with trial design and the relatively short treatment duration as potential factors. However, the extensive safety data generated confirmed AOD-9604's favorable safety profile.

Animal Studies on Fat Metabolism

Preclinical research in obese Zucker rats and other animal models provided the foundation for human trials:

• Chronic administration reduced body fat accumulation without affecting food intake
• Enhanced fatty acid oxidation rates were observed in treated animals
• No effect on lean body mass, confirming selective action on adipose tissue
• Improved lipid profiles in some models, with reduced circulating triglycerides

Cartilage and Joint Research

Following the obesity program's discontinuation, researchers explored AOD-9604's regenerative potential:

A 2012 study in the Journal of Orthopaedic Research examined AOD-9604 in a sheep model of cartilage damage. The results showed improved cartilage regeneration compared to controls, with enhanced proteoglycan content and improved histological appearance of repaired tissue. These findings prompted further investigation into joint health applications.

In vitro studies on human chondrocytes demonstrated that AOD-9604 stimulates synthesis of key cartilage matrix components—proteoglycans and collagen. The peptide also appeared to enhance chondrocyte proliferation, suggesting potential for cartilage tissue restoration.

📝 Research Status: While cartilage research shows promise, clinical trials specifically evaluating AOD-9604 for osteoarthritis or joint repair in humans remain limited. Most current evidence comes from preclinical models and in vitro studies.

Oral Bioavailability Research

One of AOD-9604's notable properties is its demonstrated oral activity. Metabolic Pharmaceuticals developed sublingual lozenge formulations that achieved systemic absorption while bypassing hepatic first-pass metabolism. In 2010, AOD-9604 received FDA Generally Recognized as Safe (GRAS) status for use in food products, though this pertained to a specific calcium supplement formulation rather than therapeutic claims.

Dosage and administration

AOD-9604 dosing protocols in research settings vary considerably, reflecting its different routes of administration and evolving research focus. All dosing information derives from clinical trials and preclinical research—not approved therapeutic use.

Clinical Trial Dosing

Human clinical trials for obesity utilized the following protocols:

| Route | Dose Range | Frequency | Trial Duration |

| --- | --- | --- | --- |

| Subcutaneous | 100-400 μg/day | Once daily | 12-24 weeks |

| Oral (lozenge) | 1-10 mg/day | Once daily | 12-24 weeks |

The higher oral doses reflect the reduced bioavailability compared to injection. Sublingual lozenges were designed to maximize absorption through the oral mucosa while minimizing gastrointestinal degradation.

Research Protocols

Current research settings often employ subcutaneous injection due to its reliable pharmacokinetics:

1

Starting Dose

Many protocols begin at 250-300 μg once daily, typically administered in the morning on an empty stomach.

2

Administration Timing

Due to AOD-9604's short half-life (5-7 minutes), some protocols split dosing into 2-3 daily administrations for sustained exposure.

3

Cycle Duration

Research protocols typically span 8-16 weeks, reflecting the clinical trial durations that showed effects on body composition.

⚠️ Short Half-Life Consideration: AOD-9604's plasma half-life of approximately 5-7 minutes is exceptionally short. The biological effects may persist longer due to intracellular signaling cascades triggered by the peptide, but the short half-life has implications for dosing strategy.

Reconstitution

Standard peptide reconstitution practices apply:

• Reconstitute lyophilized powder with bacteriostatic water or sterile water
• Add diluent slowly down the vial wall; do not shake or agitate
• Allow to dissolve completely before drawing doses
• Store reconstituted solution at 2-8°C and use within 21 days
• Lyophilized powder should be stored at -20°C for long-term stability

Injection Site

Subcutaneous injection sites commonly include the abdominal region (rotating around the umbilicus) or the thigh. Some protocols suggest injecting near the target fat area, though systemic distribution makes injection site selection less critical than with some other peptides.

Research Context

Fasting administration is often employed to maximize AOD-9604's lipolytic effects, as insulin elevation from feeding may attenuate fat-burning signaling pathways.

Safety and side effects

AOD-9604 benefits from substantial human safety data generated during clinical trials. This distinguishes it from many research peptides that lack formal human studies.

Clinical Trial Safety Profile

Across multiple Phase 1, 2, and 2b/3 clinical trials involving hundreds of participants, AOD-9604 demonstrated a favorable safety profile:

✓

No IGF-1 Effects

Trials confirmed no significant changes in IGF-1 levels, eliminating concerns about growth factor-driven cell proliferation.

✓

Glucose Neutral

No effects on blood glucose or insulin sensitivity were observed, unlike full growth hormone.

✓

No Serious Events

No serious adverse events were attributed to AOD-9604 in published clinical trial data.

Reported Side Effects

Side effects observed in clinical trials were generally mild and transient:

• Injection site reactions: Redness, mild swelling, or discomfort at injection sites—common with any peptide injection
• Headache: Occasional reports, typically mild and self-limiting
• Indigestion: Some participants reported mild gastrointestinal symptoms
• Fatigue: Transient tiredness noted in some cases

These effects generally did not require intervention and resolved on their own. The incidence was often comparable to placebo groups, suggesting some reports may not be peptide-related.

⚠️ Important Limitations: Clinical trial data covers treatment periods of up to 24 weeks. Long-term safety beyond this duration is not established. Additionally, research-grade peptides from non-pharmaceutical sources may vary in purity and composition, introducing variables not present in clinical trials.

Metabolic Safety

Key safety differentiators from growth hormone include:

• No observed effect on growth hormone or IGF-1 levels
• No impact on glucose homeostasis or insulin sensitivity
• No changes in thyroid hormone levels
• No significant effects on other hormone panels

Regulatory and Doping Considerations

AOD-9604 is not approved by the FDA for any therapeutic indication. It is classified as a research chemical. The peptide is prohibited by WADA in competitive sports, regardless of its actual performance-enhancing effects. Athletes should be aware that use would constitute a doping violation.

Contraindications and Precautions

While formal contraindications have not been established due to the lack of regulatory approval, caution would be reasonable for:

• Individuals with active cancer or history of cancer (growth-promoting effects cannot be fully ruled out)
• Pregnancy and breastfeeding (no safety data available)
• Pediatric populations (not studied in children)
• Individuals with known hypersensitivity to peptide compounds